<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02614820</url>
  </required_header>
  <id_info>
    <org_study_id>JZheng</org_study_id>
    <nct_id>NCT02614820</nct_id>
  </id_info>
  <brief_title>The Safety, Efficacy and Tolerability of Remote Ischemic Preconditioning as a Therapy to DMD</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>General Hospital of Chinese Armed Police Forces</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>General Hospital of Chinese Armed Police Forces</source>
  <brief_summary>
    <textblock>
      Background: Duchenne muscular dystrophy (DMD) is an X chromosome recessive hereditary disease
      and mainly characterized by progressive muscle weakness and atrophy. Glucocorticoid is the
      only proven effective medicine,while side effects limit its use. Recent studies have shown
      that the vascular density in the DMD patients' muscle is decreased,so muscle are in ischemic
      and anoxic. Remote ischemic preconditioning(RIPC) can improve the capable of resistanting
      ischemia and hypoxia and maybe a potential therapy for DMD patients.

      Methods: 100 patients (aged 2 to 6 years)will be divided into two groups(treatment and
      control groups) randomly. Treatment group will receive an RIPC stimulus (inflation of a blood
      pressure cuff on the bilateral thighs to 150 mm Hg for four 5-minute intervals) while control
      group will receive a similar stimulus (inflation of a blood pressure cuff on the bilateral
      thighs to 40 mm Hg for four 5-minute intervals). Serum kinase level ,Blood levels of
      myoglobin, Evaluation of motor function(Four steps test;6-minute walking test) and MRI of
      lower limbs）at 0 days, 3 days, 3months ,6months.

      Purpose：

        1. To evaluate the safety and tolerability of remote ischemic preconditioning for DMD
           patients

        2. To identify the effectiveness of remote ischemic preconditioning for DMD patients.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum CK value</measure>
    <time_frame>0 day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum CK value</measure>
    <time_frame>3 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum CK value</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum CK value</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum myoglobin values</measure>
    <time_frame>0 day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum myoglobin values</measure>
    <time_frame>3 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum myoglobin values</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Serum myoglobin values</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>6-minute walking test</measure>
    <time_frame>0 day</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>6-minute walking test</measure>
    <time_frame>3 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>6-minute walking test</measure>
    <time_frame>3 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>6-minute walking test</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>T2 values</measure>
    <time_frame>0 day</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>T2 values</measure>
    <time_frame>3 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>T2 values</measure>
    <time_frame>3 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>T2 values</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Duchenne Muscular Dystrophy (DMD)</condition>
  <arm_group>
    <arm_group_label>treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>inflation of a blood pressure cuff on the bilateral thighs to 150 mm Hg for four 5-minute intervals</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>inflation of a blood pressure cuff on the bilateral thighs to 40 mm Hg for four 5-minute intervals</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Remote Ischemic Preconditioning Training Apparatus</intervention_name>
    <arm_group_label>treatment group</arm_group_label>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:Genetic analysis of DMD; from 2 to 6 years old ;without other diseases .

        Exclusion Criteria: other congenital diseases;upper respiratory infection, gastroenteritis,
        vaccination, trauma.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>6 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>wu shiwen, Dr.</last_name>
    <phone>13910238117</phone>
    <email>wu_shiwen@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shiwen wu</name>
      <address>
        <city>BeiJing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>wu shiwen, Dr.</last_name>
      <phone>13910238117</phone>
      <email>wu_shiwen@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2015</study_first_submitted>
  <study_first_submitted_qc>November 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2015</study_first_posted>
  <last_update_submitted>November 22, 2015</last_update_submitted>
  <last_update_submitted_qc>November 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 25, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ischemic preconditioning</keyword>
  <keyword>sefety</keyword>
  <keyword>efficacy</keyword>
  <keyword>DMD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

